Real-time H&E Image-based Biomarker Profiling

Rectangle 54-2

The Power of AI: Revolutionizing and Democratizing Cancer Diagnosis - Fortune Health 2022

Our Mission

Our mission is to assist cancer patients in receiving the optimal treatment medicine can offer by leveraging AI to detect, in real-time, a broad range of cancerous biomarkers and genomic insights from H&E image. By doing so, Imagene overcomes economical, logistical, and technological barriers to reach the full potential of precision medicine for cancer patients.

Let’s Explore

Experts say about us

“Imagene’s technology can unlock precise and crucial information in real-time, changing the way cancer is diagnosed and treated.”

Group 146-2

Dr. David Agus

Founding Director and CEO

Lawrence J. Ellison Institute for Transformative Medicine

"This is a breakthrough technology that has been tested in deep collaboration with the physicians of our pathology lab" 

Mask Group

Prof. Iris Barshak

Head of Pathology

Sheba Medical Center

"We are proud to collaborate with Imagene and trust its potential to change the way we diagnose cancer patients." 

Group 136

Prof. Dov Hershkovitz

Director of Pathology

Tel Aviv Sourasky Medical Center

"Cancer diagnosis focuses on pathological and molecular testing. I believe that no structure and assumptions should become a barrier to personal treatment. Imagene brings the potential of accurate, fast, actionable, standardized screening to all cancer patients."

Mask Group

Prof. Nir Peled, MD, PhD

Director of the Oncology Dept.

Shaare Zedek Medical Center

“Our team is proud to be part of Imagene’s mission to leverage AI in the fight against cancer. The ongoing digitization of healthcare will reward medical providers, payers and patients with new ways of leveraging data to improve diagnoses, treatments and outcomes” 

Mask Group-2

Yodfat Buchris

Managing Director

Blumberg Capital

"After seeing the same type of transformation in the AI medical imaging space, we are certain that Imagene is well positioned to disrupt the pathology biomarkers space with its unique AI platform and data assets.”

Group 146

Eyal Gura

Tech Entrepreneur, Mentor & Private Investor

A New Standard for Biomarker DetectionFrom 14 days to 2 minutes

Making genomic testing accessible, leveraging the biopsy image for research and treatment optimization

Schedule a demo
bg-home-demo

Imagene for Research

Standardize, accelerate and reduce costs of drug development through deep learning for clinical trials

noto_test-tube

Clinical Trials

noto_microscope

Precision Oncology

noto_pill

Drug Development

Imagene for Clinical

Supporting clinical decision-making by providing clinicians with a real-time molecular report using only the scanned image of an H&E-stained biopsy slide

icon-real-time-diagnosis

Real-time Diagnosis

icon-image-only

Image Only (no tissue required)

icon-accuracy-levels

Accuracy levels of diagnostic tests

icon-optimized-treatment-plans

Optimized treatment plans

vector-home-clinical

Imagene in Numbers

Organs

Group 5

Models

Group 6
%

avg Sensitivity

Group 7
%

avg Specificity

Group 8
bg-home-numbers
img-technology

Our Technology

lmagene's state-of-the-art deep learning models have the capabilities of searching for all present phenotypic alterations and empowering the reporting of meaningful insights.

We make no assumptions. our models rely on prospective data and unsupervised learning to provide the highest sensitivity and specificity rates.

Book a Demo

Join our Partners

logo-partners-1 logo-partners-2 logo-partners-3
Learn More About Us
vector-jhome-partners-1
vector-jhome-partners-2